Schrodinger, Inc. Common Stock SDGR

Schrodinger, Inc. es un proveedor de soluciones de software computacional para el descubrimiento de medicamentos en la industria biofarmacéutica. La compañía opera a través de dos segmentos: Software y Descubrimiento de Medicamentos. El segmento de Software se enfoca en licenciar el software de la compañía para el descubrimiento molecular. El segmento de Descubrimiento de Medicamentos se enfoca en construir un portafolio de programas de medicamentos preclínicos y clínicos, internamente y a través de colaboraciones. La plataforma de software basada en física de la compañía permite el descubrimiento de moléculas para el desarrollo de medicamentos y aplicaciones de materiales. Su plataforma de software es utilizada por compañías biofarmacéuticas e industriales, instituciones académicas y laboratorios gubernamentales. El pipeline de la compañía incluye CDC7, Wee1, MALT1, HIF-2 alfa y SOS1/KRAS. Su CDC7 es un inhibidor de moléculas pequeñas para el tratamiento de tumores sólidos y líquidos.

• GlobeNewswire Inc. 5 oct

  Global Drug Discovery AI Tools Market - Strategic Forecast 2026-2032 | Generative AI, Cloud Platforms, and Integrated R&D Workflows Create New Growth Opportunities

  A comprehensive market research report examines the growing role of AI tools in drug discovery, covering applications in target identification, molecular design, and preclinical testing. The market is shifting from isolated computational experiments toward integrated workflows combining data systems and laboratory validation. Success depends on data quality, model interpretability, regulatory compliance, and multidisciplinary expertise across biology, chemistry, and data science.

  

• GlobeNewswire Inc. 23 sept

  Biosimulation Market Set for Strong Growth Through 2035, Fueled by AI-Driven Drug Discovery, Virtual Trials and Precision Medicine Demand

  The global biosimulation market reached USD 4.09 billion in 2025 and is projected to grow at 16.90% CAGR through 2035, reaching USD 19.49 billion. Growth is driven by AI-driven drug discovery, virtual clinical trials, personalized medicine demand, and computational modeling adoption. However, geopolitical instability in the Middle East has created near-term supply chain disruptions and increased pharmaceutical packaging costs by 15-20%. Key players are pursuing strategic acquisitions and platform launches to expand capabilities.

  

• GlobeNewswire Inc. 10 jul

  Generative AI in Drug Discovery: Revolutionizing Pharmaceutical Research and Development

  The generative AI in drug discovery market is experiencing significant expansion, growing from $0.25 billion in 2025 to $0.33 billion in 2026, with projections to reach $0.86 billion by 2030 at a 27% CAGR. Key drivers include rising drug development costs, computational chemistry advancements, increased biological datasets, and strategic collaborations between AI firms and pharmaceutical companies. Major players are leveraging AI-driven tools for molecule generation, deep learning in drug design, and accelerated early-stage development.

  

• Benzinga 16 jun

  The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It

  The AI drug discovery field is shifting focus from building the most powerful models to establishing trustworthy, connected biological data foundations. MindWalk Holdings (HYFT) has positioned itself as a leader in this 'context layer' approach with its ReefIQ and LensAI platforms, reporting 52% YoY revenue growth and its first recurring platform contract. The article examines how this represents a maturation of the sector beyond initial hype, comparing MindWalk's strategy to peers like Absci, Recursion, Schrödinger, and Certara.